文献速递银屑病与炎症性皮肤病皮肤感染

系统治疗银屑病患者严重感染风险的大型队列研究

Serious infections among a large cohort of subjects with systemically treated psoriasis.
PubMed 文献 · J Am Acad Dermatol · 2017-09-13

在Kaiser Permanente Northern California医疗系统中,5889例曾接受系统治疗的成人银屑病患者随访29717人年,比较生物制剂与非生物制剂系统治疗的严重感染发生率。调整年龄、性别、种族和合并症后,生物制剂组总体严重感染风险显著升高(aHR 1.31,95%CI 1.02-1.68),皮肤软组织感染(aHR 1.75,95%CI 1.19-2.56)和脑膜炎(aHR 9.22,95%CI 1.77-48.10)风险在生物制剂活跃使用期显著增加。

要点

  • 生物制剂治疗银屑病者总体严重感染风险较非生物制剂系统治疗者升高(aHR 1.31)。
  • 皮肤软组织感染风险在生物制剂活跃使用期显著升高(aHR 1.75)。
  • 脑膜炎风险信号显著升高(aHR 9.22),处方生物制剂时应警惕。

核心结论

  • 生物制剂治疗银屑病患者总体严重感染风险较非生物制剂系统治疗者显著升高(aHR 1.31,95%CI 1.02-1.68)。
  • 皮肤软组织感染和脑膜炎风险在生物制剂活跃使用期显著增加。

研究设计与样本

  • 基于社区医疗系统Kaiser Permanente Northern California的回顾性队列研究。
  • 纳入5889例曾接受系统治疗的成人银屑病患者,随访29717人年。
  • 采用Cox回归计算调整风险比(aHR),调整年龄、性别、种族或民族及合并症。

主要发现

  • 总体严重感染aHR为1.31(95%CI 1.02-1.68),生物制剂组风险显著高于非生物制剂组。
  • 皮肤软组织感染aHR为1.75(95%CI 1.19-2.56),见于生物制剂活跃使用期。
  • 脑膜炎aHR为9.22(95%CI 1.77-48.10),见于生物制剂活跃使用期。

临床怎么用

  • 处方生物制剂时应告知患者严重感染风险,尤其是皮肤软组织感染和脑膜炎。
  • 对使用生物制剂的银屑病患者,需警惕感染相关症状并及时评估。

局限性

  • 未分析单个药物相关的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biologic therapy is effective for treatment of moderate-to-severe psoriasis but may be associated with an increased risk for serious infection. OBJECTIVE: To estimate the serious infection rate among patients with psoriasis treated with biologic as compared with nonbiologic systemic agents within a community-based health care delivery setting. METHODS: We identified 5889 adult Kaiser Permanente Northern California health plan members with psoriasis who had ever been treated with systemic therapies and calculated the incidence rates and 95% confidence intervals (CIs) for serious infections over 29,717 person-years of follow-up. Adjusted hazard ratios (aHRs) were calculated using Cox regression. RESULTS: Adjusting for age, sex, race or ethnicity, and comorbidities revealed a significantly increased risk for overall serious infection among patients treated with biologics as compared with those treated with nonbiologics (aHR, 1.31; 95% CI, 1.02-1.68). More specifically, there was a significantly elevated risk for skin and soft tissue infection (aHR, 1.75; 95% CI, 1.19-2.56) and meningitis (aHR, 9.22; 95% CI, 1.77-48.10) during periods of active biologic use. LIMITATIONS: Risk associated with individual drugs was not examined. CONCLUSION: We found an increased rate of skin and soft tissue infections among patients with psoriasis treated with biologic agents. There also was a signal suggesting increased risk for meningitis. Clinicians should be aware of these potential adverse events when prescribing biologic agents.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Dobry AS, Quesenberry CP, Ray GT, et al. Serious infections among a large cohort of subjects with systemically treated psoriasis. J Am Acad Dermatol. 2017. PMID: 28917384. doi:10.1016/j.jaad.2017.07.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。